← Leaderboards
Blanca I Restrepo
University Of Texas Hlth Sci Ctr Houston
$3,492,591
Attributed
$7,409,167
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,409,167 · 6
By mechanism
R01$6,150,771 · 3
R21$1,258,396 · 3
Top collaborators
- Katharina Ronacher5 shared
- Leanie Kleynhans3 shared
- Jordi B Torrelles3 shared
- Joanne Turner3 shared
- Marcel Yotebieng3 shared
- Chinnaswamy Jagannath2 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Janelle Rios$5,577,129
- Rodrigo Morales$8,127,531
- Frank G Moody$853,471
- Chinnaswamy Jagannath$18,759,576
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisGrowthPhenotypeLungAffectNon-Insulin-Dependent Diabetes MellitusCytokineMonocyteResponseCellsInfectionParticipantPathogenHigh PrevalenceImmuneDiabetes MellitusTexasInflammationPredispositionMacrophageChronicImmune SystemInterleukin-6
Grant awards (17)
Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas$848,724
R01 · FY2025 · AI
Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas$887,558
R01 · FY2024 · AI
Immune and metabolic dysfunction during aging in human cohorts$578,121
R01 · FY2024 · AG · contact PI
Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas$956,440
R01 · FY2023 · AI
Immune and metabolic dysfunction during aging in human cohorts$580,104
R01 · FY2023 · AG · contact PI
Immune and metabolic dysfunction during aging in human cohorts$574,509
R01 · FY2022 · AG · contact PI
Role of metabolic Me-macrophages in the pathogenesis of tuberculosis during diabetes$197,530
R21 · FY2021 · AI · contact PI
Role of metabolic Me-macrophages in the pathogenesis of tuberculosis during diabetes$245,374
R21 · FY2020 · AI · contact PI
Altered immune-endocrine axis in type 2 diabetes and tuberculosis risk$336,930
R01 · FY2019 · AI
Altered immune-endocrine axis in type 2 diabetes and tuberculosis risk$340,941
R01 · FY2018 · AI
Altered immune-endocrine axis in type 2 diabetes and tuberculosis risk$347,839
R01 · FY2017 · AI
Altered immune-endocrine axis in type 2 diabetes and tuberculosis risk$349,605
R01 · FY2016 · AI
Altered immune-endocrine axis in type 2 diabetes and tuberculosis risk$350,000
R01 · FY2015 · AI
Uncontrolled diabetes, immune dysregulation and tuberculosis$187,500
R21 · FY2010 · AI · contact PI
Uncontrolled diabetes, immune dysregulation and tuberculosis$225,000
R21 · FY2009 · AI · contact PI
Rapid characterization of mycobacteria and drug resistance in paucibacillary TB$180,242
R21 · FY2007 · AI · contact PI
Rapid characterization of mycobacteria and drug resistance in paucibacillary TB$222,750
R21 · FY2006 · AI · contact PI